Asked by: Stella Creasy (Labour (Co-op) - Walthamstow)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of the restriction on pursuing clinical negligence cases to direct financial dependents only in cases where an individual has died on the justice system.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Freddie van Mierlo (Liberal Democrat - Henley and Thame)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what support for training and resources his Department is providing to integrated care boards to help implement the NHS England Maternal Care Bundle, published on 6 January 2026.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Laurence Turner (Labour - Birmingham Northfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he will make an assessment of the potential merits of measures in the Rhode Island Latex Gloves Safety Act 2024 to help prevent latex allergy harm in England.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is working closely with a range of stakeholders across the Government, the National Health Service, voluntary organisations, and patient representative groups to consider how allergy care and support could be improved.
The Expert Advisory Group on Allergy met most recently on 3 December and continues to bring together key stakeholders to inform policymaking and identify priorities in relation to the holistic care of people with allergies.
In terms of the use of gloves for medical purposes, the NHS purchases examination and surgical gloves through NHS Supply Chain’s two national frameworks and, ultimately, it is the choice of NHS trusts which gloves they wish to procure. Regarding examination gloves, latex was once the most commonly used glove, but nitrile, latex-free, gloves are now the most common choice. There are also ‘specialist examination gloves’ available, which aim to provide a reduction in allergy irritation.
Surgical glove purchase decisions are generally more clinically lead, and the choice of manufacturer and glove is usually made by the surgeon or consultant. There are latex and latex-free options available via the Surgical Glove Framework.
Asked by: Tom Tugendhat (Conservative - Tonbridge)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the reasons people with brain cancer are seeking treatment outside the UK, particularly in Germany, including the trend in the level of such treatments.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Ensuring patients have access to the latest and most effective treatment options is a top priority for the Government.
That is why we are committed to supporting an innovative clinical research ecosystem in the United Kingdom so that patients in this country can be among the first to benefit as we make the National Health Service fit for the future.
The Government is supportive of Scott Arthur’s Private Members Bill on rare cancers, which will make it easier for clinical trials into rare cancers, such as brain cancers, to take place in England by ensuring the patient population can be easily contacted by researchers. This will ensure that the NHS will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options, and ultimately boost survival rates.
Asked by: Freddie van Mierlo (Liberal Democrat - Henley and Thame)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he is taking steps to ensure that all patients with suspected leukaemia symptoms can access a full blood count test within 48 hours, as recommended by the NICE NG12 guidelines.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is determined to take all the necessary steps to improve early diagnosis for all cancers, including blood cancers such as leukaemia.
To accomplish this, the National Health Service is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways.
The National Institute for Health and Care Excellence (NICE) has a guideline on suspected cancer called ‘recognition and referral’ which aim to support the identification of children, young people and adults with symptoms that could be caused by cancer’. The guideline provides guidance on appropriate investigations in primary care, and the selection of people to refer for a specialist opinion. The guideline recommends that people with specific symptoms should be offered a very urgent full blood count to assess for leukaemia. Local NHS organisations are expected to take NICE guidelines fully into account in ensuring that their services meet the needs of their local populations. The NHS is held to account to deliver guidelines, which include all NICE directions, at local and regional level.
The National Cancer Plan for England will cover the entirety of the cancer pathway, from referral and diagnosis to treatment and ongoing care, as well as prevention. The plan will seek to improve every aspect of cancer care to better the experience and outcomes for all patient groups, including leukaemia patients.
Asked by: Andrew Snowden (Conservative - Fylde)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the average length of time of a GP appointment.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: John Hayes (Conservative - South Holland and The Deepings)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many people have been diagnosed with (1) Chrohn's and (2) Colitis in (a) South Holland and the Deepings and (b) Lincolnshire in each of the last five years.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Neither the Department nor NHS England hold data on the total number of people diagnosed with Crohn’s disease or colitis in South Holland and the Deepings or Lincolnshire in each of the last five years. However, the following table shows a count hospital admissions (FAEs) where there was a primary diagnosis Crohn's disease or colitis and where the patient was resident in Lincolnshire or South Holland and the Deepings, each year from 2020/21 to 2024/25:
Year | South Holland and Deepings | Lincolnshire | ||
Crohn’s | Colitis | Crohn’s | Colitis | |
2020/21 | 125 | 305 | 2,350 | 3,355 |
2021/22 | 175 | 410 | 2,765 | 4,295 |
2022/23 | 180 | 480 | 3,130 | 4,890 |
2023/24 | 165 | 465 | 3,390 | 5,275 |
2024/25 | 75 | 190 | 3,675 | 6,455 |
Source: Hospital Episode Statistics, published by NHS England
Notes:
Asked by: Tim Farron (Liberal Democrat - Westmorland and Lonsdale)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 10 May 2023 to Question 183643 on Public Health, what methodologies were used to estimate the costs to the NHS for each of the five risk factors specified.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The applicable methodologies for the National Health Service cost attributed to each of the risk factors outlined are explained in the following reports.
The estimated air pollution related costs to the NHS can be found in the Public Health England report ‘Estimation of costs to the NHS and social care due to the health impacts of air pollution: summary report’ , from 2018, which is available at the following link:
https://www.gov.uk/government/publications/air-pollution-a-tool-to-estimate-healthcare-costs
An estimate of the NHS and healthcare costs of alcohol from 2021/22, produced by the Institute of Alcohol Studies, can be found at the following link:
https://www.ias.org.uk/factsheet/economy/
Estimated obesity related costs to the NHS can be found in the Frontier Economics report for NESTA, published in July 2025, ‘The Economic and Productivity Costs of Obesity and Overweight in the UK’, which is available at the following link:
Estimated Hypertension related costs to the NHS can be found in the Optimity Matrix Cost-effectiveness review of blood pressure interventions, ‘A Report to the Blood Pressure System Leadership Board’, published November 2014, available at the following link:
The most recent estimated smoking related costs to the NHS can be found in the press release, ‘New figures show cost of smoking to society in England dwarfs tobacco tax revenue’. This is available at the following link:
Asked by: Luke Murphy (Labour - Basingstoke)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps are being taken to reduce access to treatment variations between ICBs for people with arthritis.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is committed to improving timely diagnosis and management of arthritis and other musculoskeletal (MSK) conditions across England.
The National Institute for Health and Care Excellence (NICE) has published guidance to support health and care professionals in the early diagnosis and management of rheumatoid arthritis and osteoarthritis. These guidelines help ensure that patients receive evidence-based care as early as possible.
NHS England is working to improve early diagnosis rates through its Getting It Right First Time (GIRFT) rheumatology programme. This initiative focuses on reducing variation in care, improving referral pathways, and ensuring patients with suspected arthritis and other MSK conditions are assessed promptly by specialists.
The Government has funded NHS England’s GIRFT programme to deploy its proven Further Faster model for MSK community services. The programme has been designed to reduce waiting times for community MSK appointments and to enhance access to quality treatment, working with integrated care board leaders to improve data and metrics and referral pathways to wider support services.
We are working together to further develop the approach to better enable integrated care systems to commission the delivery of high quality MSK services in the community, which will benefit patients now and into the future.
Asked by: Alex Brewer (Liberal Democrat - North East Hampshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will include information in the Green Book on the HPV vaccine that includes reference to its role in reducing the risk of oral cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Green Book is written for healthcare professionals. The chapter on human papillomavirus (HPV) does highlight the causal link between infection with this virus, cervical cancer, and some non-cervical cancer including those of the head and neck. The HPV chapter 18a from the Green Book is available at the following link:
https://www.gov.uk/government/publications/human-papillomavirus-hpv-the-green-book-chapter-18a
Broader UK Health Security Agency guidance on HPV also highlights the protection the vaccine provides against HPV infection and related conditions. This public‑facing information also explains that the vaccine helps protect against cancers of the mouth and is available at the following link:
It also highlights that the greatest risk comes from infection with high-risk types of HPV. There is very good evidence that the vaccine in use in the United Kingdom offers excellent protection against these high-risk types.